Association between triglyceride glucose index and worsening heart failure in significant secondary mitral regurgitation following percutaneous coronary intervention

Table 2 Risk of incident outcomes for the TyG index

Events/no. at risk		Model 1^a		Model 2^b		Model 3^c
Events/no. at risk		HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Worsening HF
Per 0.1 unit increase		1.03 (1.02–1.08)	< 0.001	1.06 (1.04–1.09)	< 0.001	1.07 (1.05–1.10)	< 0.001
Tertile 1	48/309	Ref.		Ref.		Ref.
Tertile 2	48/306	1.04 (0.70–1.56)	0.838	1.09 (0.73–1.63)	0.684	1.31 (0.82–2.07)	0.249
Tertile 3	81/307	1.88 (1.32–2.69)	0.001	2.02 (1.41–2.90)	< 0.001	2.44 (1.59–3.72)	< 0.001
MACE
Per 0.1 unit increase		1.03 (1.01–1.05)	0.005	1.04 (1.02–1.06)	< 0.001	1.05 (1.02–1.07)	< 0.001
Tertile 1	75/309	Ref.		Ref.		Ref.
Tertile 2	70/306	1.03 (0.74–1.43)	0.856	1.03 (0.70–1.53)	0.871	1.06 (0.71–1.60)	0.773
Tertile 3	96/307	1.48 (1.10–2.01)	0.011	1.66 (1.22–2.26)	0.001	1.90 (1.31–2.76)	0.001

^aUnadjusted
^bAdjusted for age, gender, left ventricular ejection fraction
^cAdjusted for age, gender, smoking history, body mass index, left ventricular ejection fraction, hyperlipidemia, hypertension, diabetes mellitus, anemia, chronic kidney disease, acute myocardial infarction and atrial fibrillation, and renin–angiotensin–aldosterone system inhibitor, beta-blockers, loop diuretics, and mineralocorticoid receptor antagonist
CI confidence interval, HR hazard ratio, MACE major adverse cardiovascular events, Worsening HF worsening heart failure

ISSN: 1475-2840